KEI Research Note 2020:2 Role of Private Sector, Governments and Charities in Funding Research and Development Related to Tocilizumab

KEI Research Note 2020:2 Role of Private Sector, Governments and Charities in Funding Research and Development Related to Tocilizumab
Luis Gil Abinader, May 28, 2020.

From the Introduction:

The funding of R&D for tocilizumab can be described as having three phases. The invention and early development of tocilizumab was supported by the government of Japan. Once the drug entered the market, most but certainly not all of the R&D related to tocilizumab was funded by industry, including initially by Roche or companies acquired by Roche. More recently, and certainly as regards R&D related to COVID-19, governments have played the leading role in funding R&D, including governments outside the United States.

KEI_Research_Note_2020_2_Government_Funding_IP_Tocilizumab (PDF)